ENANTA PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $331.92M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 16, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | During market hours | $14.40M | $-0.67 | – |
| Q2 FY2026 Ended Mar 31, 2026 | May 11, 2026 | During market hours | $17.20M | $-0.45 | – |
| Q1 FY2026 Ended Dec 31, 2025 | Feb 9, 2026 | During market hours | $18.60M | $-0.42 | – |
| Q4 FY2025 Ended Sep 30, 2025 | Nov 17, 2025 | During market hours | $15.10M | $-0.87 | – |
| Q3 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | During market hours | $18.30M | $-0.85 | – |
| Q1 FY2025 Ended Dec 31, 2024 | Feb 10, 2025 | During market hours | $17.00M | $-1.05 | – |
| Q4 FY2024 Ended Sep 30, 2024 | Nov 25, 2024 | During market hours | $14.60M | $-1.36 | – |
| Q3 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | During market hours | $18.00M | $-1.07 | – |
| Q2 FY2024 Ended Mar 31, 2024 | May 6, 2024 | During market hours | $17.10M | $-1.47 | – |
| Q1 FY2024 Ended Dec 31, 2023 | Feb 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Sep 30, 2023 | Nov 20, 2023 | During market hours | – | – | – |
Press releases
Announcements Enanta Pharmaceuticals filed with the SEC
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the
Regulation FD disclosure · EX-99.1 to Form 8-K
Forward Looking Statements Disclaimer This presentation contains
Regulation FD disclosure · EX-99.2 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended September 30, 2025
Results of operations · EX-99.1 to Form 8-K
Phase 2b Study of Zelicapavir in
Regulation FD disclosure · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 2 Study of Zelicapavir in
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K
Company Logo Corporate Presentation June 7, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
Results of operations · EX-99 to Form 8-K
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET ®
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
Results of operations · EX-99.1 to Form 8-K